Nelipepimut-S (NPS)
HER2 Low-Expressing Breast Cancer
Key Facts
About SELLAS Life Sciences
SELLAS Life Sciences is dedicated to advancing targeted immunotherapies for cancer, with a core focus on its WT1-targeting platform. Its most advanced candidate, galinpepimut-S, is in Phase 2/3 development for acute myeloid leukemia (AML) and malignant pleural mesothelioma. The company operates as a lean, clinical-stage organization, leveraging its expertise in antigen-specific vaccines to address significant unmet medical needs in oncology.
View full company profileAbout SELLAS Life Sciences
SELLAS Life Sciences is dedicated to advancing targeted immunotherapies for cancer, with a core focus on its WT1-targeting platform. Its most advanced candidate, galinpepimut-S, is in Phase 2/3 development for acute myeloid leukemia (AML) and malignant pleural mesothelioma. The company operates as a lean, clinical-stage organization, leveraging its expertise in antigen-specific vaccines to address significant unmet medical needs in oncology.
View full company profile